- Royal Bank of Canada has started off coverage on the biotech company Inovio Pharmaceuticals ( NASDAQ: INO ) with a sector perform rating issued in a research note on Tuesday.
- Earlier in the day, Inovio announced its plans to cutback its workforce by about 18% that will record a one-time restructuring charge of ~$1.6M in Q3 2022.
- Shares are up 6% mid-day , Tuesday, to trade at $1.96 vs. 52-week trading range of $1.39 to $9.96.
- Seeking Alpha Quant rating is at Hold for INO same as Wall Street analysts' rating .
For further details see:
Inovio Pharmaceuticals slotted at Sector Perform by RBC Capital in initial rating look